111437-10-6

Basic information

• Product Name: (5-AMino-2-Methylphenyl)Methanol
• Synonyms: (5-AMino-2-Methylphenyl)Methanol;5-Amino-2-methylbenzenemethanol;5-Amino-2-methylbenzyl alcohol
• CAS NO: 111437-10-6
• Molecular Formula: C₈H₁₁NO
• Molecular Weight: 137.17904
• Mol File: 111437-10-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Solubility: Dichloromethane, Ethyl Alcohol, Methanol
• CAS DataBase Reference: (5-AMino-2-Methylphenyl)Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (5-AMino-2-Methylphenyl)Methanol(111437-10-6)
• EPA Substance Registry System: (5-AMino-2-Methylphenyl)Methanol(111437-10-6)

Safety Data

• Hazardous Substances Data: 111437-10-6(Hazardous Substances Data)

Usage

Uses

5-Amino-2-methylbenzenemethanol is an intermediate in the synthesis of 8-Hydroxymethyl Riboflavin which is an impurity of Riboflavin (R414995), a nutritional factor found in milk, eggs, malted barley, liver, kidney, heart, leafy vegetables. Richest natural source is yeast. Minute amounts present in all plant and animal cells. Vitamin (enzyme cofactor).

Upstream product

• 18595-12-5 methyl 5-amino-2-methylbenzoate 
• 1975-52-6 5-nitro-o-toluic acid 
• 67-56-1 methanol 
• 22474-47-1 (2-methyl-5-nitro-7-phenyl)methanol 
• 2840-04-2 5-amino-2-methylbenzoic acid 
• 58966-24-8 2-(chloromethyl)-4-nitrotoluene 

Downstream Products

• 95-64-7 4-amino-o-xylene 
• 72255-68-6 6-(3-Chloromethyl-4-methyl-phenylamino)-1H-pyrimidine-2,4-dione 
• 144735-36-4 C₃₈H₃₄N₃O₂P 

Relevant articles and documents

PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH

Provided herein are Pyrazole Pyrazine Amine Compounds having the following structure:Formula (I). Wherein Q and R1-R3 are as defined herein, compositions comprising an effective amount of a Pyrazole Pyrazine Amine Compound and methods for treating or preventing inflammatory conditions, immunological conditions, cancer, neurodegenerative diseases, age-related diseases, cardiovascular diseases and metabolic conditions, or conditions treatable or preventable by inhibition of an IKK, or an IKK pathway, comprising administering an effective amount of a Pyrazole Pyrazine Amine Compound to a patient in need thereof.

One pot preparation of pyrido[2,3,4-de] quinazolines and benzo[de][1,6] naphthyridines by a consecutive process involving an aza-Wittig/ electrocyclic ring-closure/heterocumulene-mediated annelation or intramolecular Diels-Alder cycloaddition sequence

Aza Wittig-type reaction of bis(iminophosphorane)1 with one mole of isocyanate leads to the iminophosphoranes 5 which by treatment with a second mole of isocyanate afforded pyrido[2,3,4-de]quinazolines 6. Similarly, reaction with ketenes leads to the formation of benzo[de][1,6] naphthyridines 9. Direct conversion 1→6 and 1→9 were achieved using two moles of isocyanate or ketene respectively.